Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
Gross Profit | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
EBITDA | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
Net Income | 820.47M | 546.02M | -695.26M | -984.05M | -1.04B |
Balance Sheet | |||||
Total Assets | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
Cash, Cash Equivalents and Short-Term Investments | 772.96M | 1.01B | 833.66M | 154.98M | 1.11B |
Total Debt | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
Total Liabilities | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
Stockholders Equity | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | |||||
Free Cash Flow | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
Operating Cash Flow | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
Investing Cash Flow | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
Financing Cash Flow | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | HK$27.31B | 30.70 | 31.65% | ― | 4.23% | 47.71% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 4.78% | 11.72% | -20.69% | |
57 Neutral | HK$19.90B | ― | -6.35% | ― | 33.63% | 31.50% | |
54 Neutral | €30.60B | ― | -32.29% | ― | 43.13% | 28.93% | |
51 Neutral | HK$33.78B | ― | -19.78% | ― | 25.96% | 39.58% | |
48 Neutral | HK$26.76B | ― | -253.12% | ― | 330.23% | 59.68% |
Shanghai Henlius Biotech, Inc. has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, aimed at attracting and retaining skilled personnel to drive the company’s long-term development goals. The schemes, subject to shareholder approval, are designed to align the interests of participants with shareholders through share ownership, and include conditional grants to key personnel, such as Dr. Zhu, to enhance the company’s value and stakeholder benefits.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced proposed amendments to its Articles of Association and other corporate governance measures to align with updated legal and regulatory requirements. Additionally, the company has appointed new members to its Nomination Committee, enhancing its governance structure in accordance with revised listing rules.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced amendments to the terms of reference for its Nomination Committee, initially established in 2019. The changes emphasize the inclusion of independent non-executive directors and gender diversity within the committee, reflecting the company’s commitment to robust governance and inclusive leadership practices.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the governance structure and strategic oversight, potentially impacting the company’s future direction and market positioning.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a bridging study in Japan for HANSIZHUANG, combined with chemotherapy, targeting extensive-stage small cell lung cancer. This study aims to support the future marketing application of HANSIZHUANG in Japan, following successful international trials. The company is advancing multiple clinical studies globally, enhancing its position in the oncology market.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.
Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a Phase 1/3 clinical study of its Ipilimumab biosimilar, HLX13, for the treatment of unresectable advanced hepatocellular carcinoma in mainland China. This trial aims to assess the pharmacokinetic profiles, efficacy, safety, and immunogenicity of HLX13 compared to its reference product, YERVOY. The study’s successful progression could enhance the company’s market position in the oncology biosimilar sector, potentially impacting stakeholders positively by expanding treatment options for various cancers.
Shanghai Henlius Biotech, Inc. has been included in the MSCI Global Small Cap Indexes, effective after the market close on May 30, 2025. This inclusion is significant as the MSCI Indexes are widely referenced by international investment institutions, potentially enhancing the company’s visibility and attractiveness to investors.
Shanghai Henlius Biotech, Inc. successfully held its Annual General Meeting (AGM) on May 8, 2025, where all proposed resolutions were passed with significant shareholder support. The resolutions included the approval of the company’s annual report, board work report, board of supervisors’ work report, and final accounts report for the year 2024, reflecting strong operational performance and governance.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Sandoz AG to commercialize its HLX13, a recombinant anti-CTLA-4 fully human monoclonal antibody injection, across the United States, 42 European countries, Japan, Australia, and Canada. This agreement includes significant financial terms, such as an upfront payment of $31 million, potential milestone payments totaling $160 million, and sales milestone payments up to $110 million, along with double-digit tiered royalties. The deal is expected to enhance Henlius’s market presence in the oncology sector, leveraging Sandoz’s commercialization capabilities in major global markets.
Shanghai Henlius Biotech, Inc. has received approval in Germany for an international multi-center phase 3 clinical trial of its HLX22 monoclonal antibody in combination with other therapies for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This development marks a significant step in the company’s efforts to expand its clinical trials across multiple regions, potentially enhancing its market positioning and offering new treatment options for patients with these types of cancer.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with Alvogen Korea to commercialize its serplulimab injection, HANSIZHUANG, in South Korea. This agreement grants Alvogen Korea exclusive rights to market the drug for various cancers, potentially enhancing Henlius’s market presence in Asia and providing significant financial milestones and royalties.
Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 2 clinical study of their innovative product HLX22, in combination with trastuzumab deruxtecan, for treating HER2-low, HR-positive locally advanced or metastatic breast cancer in mainland China. This study aims to evaluate the efficacy and safety of this combination therapy, which has shown promising preclinical results, potentially offering a new therapeutic strategy for patients with HER2-expressing tumors.
Shanghai Henlius Biotech, Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 8, 2025, where shareholders will consider and approve various resolutions. These include the company’s annual report, financial accounts, profit distribution, and budget proposals for the years 2024 and 2025. Additionally, the meeting will address the re-appointment of auditors and remuneration packages. A special resolution will be considered to grant the board a mandate to issue shares, which could impact the company’s capital structure and market operations.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a phase 1b/2 clinical trial of HLX43, an antibody-drug conjugate targeting PD-L1, in combination with HANSIZHUANG for treating advanced/metastatic solid tumors in mainland China. This trial aims to evaluate the safety and efficacy of the combination therapy, which could offer more effective and safer clinical solutions, as no similar combination therapy has been approved globally.
Shanghai Henlius Biotech, Inc. announced that its phase 3 clinical study of HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has successfully met its primary endpoint. This development positions the company to potentially enter a market in mainland China where no bevacizumab products have yet been approved for wAMD, indicating a significant opportunity for growth and impact on stakeholders.